Navigation Links
AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
Date:1/12/2009

Results Show Successful Clinical Validation of Pharmacodynamic Effect

REDWOOD CITY, Calif., Jan. 12 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc., an emerging specialty pharmaceutical company focused on the treatment of intermittent and acute medical conditions with an initial emphasis on pain management, today announced positive results from a Phase 1 clinical study evaluating the safety, tolerability and efficacy of the company's proprietary sublingual sufentanil (opioid) and triazolam (benzodiazepine) NanoTab(TM) combination product candidate (ARX-03). The product is designed to address the current unmet need for a non-invasive product to provide sedation and analgesia for an increasing number of office-based procedures.

The study demonstrated that administration of ARX-03 resulted in a statistically significant increase in sedation levels for the 10mcg sufentanil/200mcg triazolam dosage strength in both a younger cohort (age range 18-60 years; p=0.009) and an older cohort (age range of 61-80 years; p=0.003) as compared to sublingual sufentanil alone. These data were collected using the Richmond Agitation-Sedation Scale (RASS), a validated and objective test for assessment of sedation levels. The average onset of sedation was 20-30 minutes for the higher dosage strength in each study cohort.

Additionally, sublingual administration of the sufentanil/triazolam combination was found to be safe and well tolerated. Based on these positive results, AcelRx intends to further advance clinical development of ARX-03 in 2009.

"We believe the results of this trial are particularly valuable as they offer clinical evidence well beyond what is expected from a typical Phase 1 study. Not only have we shown ARX-03 to be safe and well-tolerated, we have also demonstrated significant pharmacodynamic findings with a randomized, double-blind design that spanned different age groups and multiple dosage level
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... N.Y. , March 4, 2015  Kannalife Sciences, ... MD has joined its Scientific Advisory Board to assist ... development efforts towards the use of cannabinoid therapeutics for ... is the forensic pathologist responsible for conducting the full ... Hall of Fame center for the Pittsburgh Steelers. It ...
(Date:3/4/2015)... Mar. 04, 2015 Research and Markets ... of the "Negative Pressure Wound Therapy Market ... Industry Analysis, Size, Share, Growth, Trends and Forecast ... , The global negative pressure ... and by geography. By product types the NPWT ...
(Date:3/4/2015)... Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug delivery ... the upcoming 27 th Annual ROTH Conference, taking ... CA.  Dr. Michael Berelowitz , Chairman ... a corporate overview on March 10, 2015. ...
Breaking Medicine Technology:Kannalife Sciences, Inc. Announces the Addition of Dr. Bennet Omalu, Renowned Pathologist and Founder of Chronic Traumatic Encephalopathy, to its Scientific Advisory Board 2Kannalife Sciences, Inc. Announces the Addition of Dr. Bennet Omalu, Renowned Pathologist and Founder of Chronic Traumatic Encephalopathy, to its Scientific Advisory Board 3Global Negative Pressure Wound Therapy (Conventional and Single Use NPWT Systems) Market Report 2014-2020 2Oramed to Present at the ROTH Conference 2Oramed to Present at the ROTH Conference 3
... HIGHLIGHTS:2011 Results (all percentages are to ... reported sales increased 11% to $626 million. Q3 sales grew ... sales growing organically by 4% and 2%, respectively.  Recently completed ... exchange rates contributed an additional 5% to reported sales growth ...
... Merz Pharmaceuticals, LLC, today announced that data from ... Xeomin® (incobotulinumtoxinA), a botulinum toxin type A free from ... will be presented at the 115th Annual Meeting of ... These data include an extension of the ...
Cached Medicine Technology:Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 2Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 3Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 4Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 5Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 6Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 7Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 8Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 9Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 10Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 11Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 12Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 13Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 2Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 3Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 4Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 5Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 6Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 7Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 8
(Date:3/4/2015)... (PRWEB) March 04, 2015 Starting February ... LASIK and PRK procedures at their new location in ... Dr. Joseph King and Dr. Gabriel Chu also provide ... in Surrey is named Fraser Valley Cataract and Laser ... accredited by the College of Physicians and Surgeons of ...
(Date:3/4/2015)... Alliance Healthcare Foundation (AHF), a non-profit organization working ... in San Diego and Imperial Counties, announced today that ... Grants program with awards totaling $1 million. , ... Support Grants program. Grant recipients were chosen through a ... committee, as well as the community as a whole. ...
(Date:3/4/2015)... " Optrix by Body Glove ” ... Tech Report, which takes a look at the latest ... Scott Steinberg, a special reporter for NewsWatch and a ... viewers how they have an ultra-rugged, waterproof case with ... a major player at the Consumer Electronics Show in ...
(Date:3/4/2015)... As seen on Advanced Fertility Center ... a painful condition in which the lining of the ... leading to very unpleasant symptoms and complications that greatly ... terrible effect on women’s quality of life due to ... cause of infertility in women and carries a huge ...
(Date:3/4/2015)... 04, 2015 The New Mel Brooks ... music, will be performed by the award-winning Drama Department ... this March 6-22, 2015, on Fridays, Saturdays and Sundays. ... High School (27118 Silver Spur Road, Rolling Hills ... the program or may be purchased on-line at ...
Breaking Medicine News(10 mins):Health News:King LASIK relocates to Surrey, British Columbia 2Health News:Alliance Healthcare Foundation Awards $1 million through Mission Support Grants Program 2Health News:Alliance Healthcare Foundation Awards $1 million through Mission Support Grants Program 3Health News:A Waterproof Phone Case with an Interchangeable Lens System was Featured on NewsWatch Television on January 30, 2015 2Health News:Advanced Fertility Center of Texas Brings Awareness to the Month of March-Endometriosis Awareness Month 2Health News:Advanced Fertility Center of Texas Brings Awareness to the Month of March-Endometriosis Awareness Month 3Health News:The New Mel Brooks Musical Young Frankenstein Performance March 6-March 22, 2015, by the Award Winning Drama Department at Peninsula High School, Rolling Hills 2
... the brain illness in cattle months before symptoms appear, ... A simple, inexpensive DNA blood test may be able ... before they show any clinical signs of the disease, ... BSE (bovine spongiform encephalopathy) can only be diagnosed by ...
... (BRONX, NY) Men who develop prostate cancer face an ... a so-called breast cancer gene mutation, scientists from the Albert ... issue of Clinical Cancer Research . The findings could ... treatment options. , The study, involving 979 men with ...
... DIEGO, Jan. 29 Amylin Pharmaceuticals, Inc. (Nasdaq: ... an amended 13-D filing with the Securities and Exchange ... funds announcing their intent to nominate a slate of ... 2009 annual meeting. Amylin has not yet received the ...
... to improve physical function, decrease symptoms and minimize ... pain. Numerous randomized trials and clinical practice guidelines ... individually tailored, supervised exercise programs are associated with ... a lack of knowledge about exercise prescription, including ...
... North State Bancorp (OTC,Bulletin Board: NSBC) (the "Company"), ... of $687.6 million as of December 31, 2008,compared to ... an increase,of $140.1 million or 25.6%. , ... December 31, 2008 were $612.7,million and total loans were ...
... AnnouncedPITTSBURGH, Jan. 29 invivodata inc., the ... (ePRO) solutions and services for global clinical ... 2009 -- its annual Patient Reported Outcomes ... http://www.invivodata.com/epro2009 to register for the ...
Cached Medicine News:Health News:Blood Test for 'Mad Cow' Disease May Be Near 2Health News:Gene mutations increase risk for aggressive prostate cancer 2Health News:Gene mutations increase risk for aggressive prostate cancer 3Health News:Exercise underutilized for chronic back and neck pain 2Health News:Exercise underutilized for chronic back and neck pain 3Health News:North State Bancorp Reports Profitable 2008 2Health News:North State Bancorp Reports Profitable 2008 3Health News:North State Bancorp Reports Profitable 2008 4Health News:North State Bancorp Reports Profitable 2008 5Health News:North State Bancorp Reports Profitable 2008 6Health News:invivodata Opens Registration for Annual Patient Reported Outcomes Conference 2Health News:invivodata Opens Registration for Annual Patient Reported Outcomes Conference 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: